Abstract IA26: FGFR2 fusion inhibitors: Clinical benefit and mechanisms of resistance

The fibroblast growth factor pathway (FGFR) has been implicated in a subset of hepatobiliary cancers. Predominant amongst these are fusions/rearrangements for FGFR2 in ~10-15% of intrahepatic cholangiocarcinomas. In this talk we will review: (1) the FGFR pathway and its role in normal physiology, (2) sequencing studies in cholangiocarcinoma with emphasis on discovery of FGFR2 fusions, (3) clinical data for FDA approved FGFR small molecule tyrosine kinase inhibitors, (4) clinical data for second and third generation FGFR inhibitors, (5) determinants of response to therapy for FGFR inhibitors, (6) mechanisms of resistance to FGFR inhibitors and (7) on and off target toxicities for first generation FGFR inhibitors.

Citation Format: Mitesh Borad. FGFR2 fusion inhibitors: Clinical benefit and mechanisms of resistance [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl):Abstract nr IA26.